Key Takeaways
- • Qiagen shares gained 2.1% in premarket trading on September 17, 2026, following reports that TPG and Bain Capital have joined a competitive bidding process for the molecular diagnostics company.
- • Five major private equity firms are now actively exploring acquisition offers: TPG, Bain Capital, KKR, EQT, and Advent International, with the company seeking a minimum valuation of approximately $50 per share.
- • Two prospective buyers commenced formal due diligence in August 2026, with some bidders evaluating partnerships with healthcare companies to structure or finance potential acquisitions.
- • Qiagen initiated its strategic review process in March 2026 with advisory support from Moelis & Co. and Goldman Sachs, following earlier takeover interest from EQT and Advent in July.
- • The competitive bidding environment reflects market recognition of Qiagen's core business in molecular diagnostics, sample-preparation technologies, and research products serving healthcare providers, laboratories, and pharmaceutical companies.
Summary
Qiagen N.V. is at the center of an intensifying private equity auction with a newly expanded buyer consortium. Following reports on September 17, 2026, that TPG and Bain Capital have entered the bidding process, Qiagen's share price rose 2.1% in premarket trading. The molecular diagnostics company is now fielding interest from five substantial private equity competitors: TPG, Bain Capital, KKR, EQT, and Advent International, according to Germany's Manager Magazin.
The company has established a clear price floor in negotiations, seeking a minimum offer of approximately $50 per share. This valuation target reflects investor confidence in Qiagen's market position despite the company facing headwinds earlier in 2026, with year-to-date performance declining 12.74% prior to takeover speculation.
Qiagen's sales process has advanced materially since the company announced its strategic review in March 2026. At that time, the company retained Moelis & Co. and Goldman Sachs to evaluate strategic alternatives. EQT and Advent International emerged as initial interested parties in July, followed by KKR's entry into the process. Two prospective bidders have progressed to formal due diligence as of August 2026, signaling serious acquisition intent. Some bidders are also exploring partnership structures with healthcare companies to facilitate financing or deal architecture.
Qiagen's business—which provides molecular diagnostic tests, sample-preparation technologies, and research products to healthcare providers, laboratories, and pharmaceutical companies—has attracted considerable private equity attention. The competitive bidding dynamic suggests strong conviction among multiple sponsors regarding the company's operational and strategic value, with the expanding buyer group indicating sustained momentum in the transaction process.
The company has established a clear price floor in negotiations, seeking a minimum offer of approximately $50 per share. This valuation target reflects investor confidence in Qiagen's market position despite the company facing headwinds earlier in 2026, with year-to-date performance declining 12.74% prior to takeover speculation.
Qiagen's sales process has advanced materially since the company announced its strategic review in March 2026. At that time, the company retained Moelis & Co. and Goldman Sachs to evaluate strategic alternatives. EQT and Advent International emerged as initial interested parties in July, followed by KKR's entry into the process. Two prospective bidders have progressed to formal due diligence as of August 2026, signaling serious acquisition intent. Some bidders are also exploring partnership structures with healthcare companies to facilitate financing or deal architecture.
Qiagen's business—which provides molecular diagnostic tests, sample-preparation technologies, and research products to healthcare providers, laboratories, and pharmaceutical companies—has attracted considerable private equity attention. The competitive bidding dynamic suggests strong conviction among multiple sponsors regarding the company's operational and strategic value, with the expanding buyer group indicating sustained momentum in the transaction process.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.